奥扎奈珠单抗 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "奥扎奈珠单抗" in Chinese language version.
refsWebsite
Global rank
Chinese rank
1st place
1st place
3,257th place
3,896th place
11th place
332nd place
low place
low place
5,225th place
4,888th place
als.ca
- Phase II - Ozanezumab (GSK1223249). ALS Canada. （原始内容存档于2013-05-10）.
ama-assn.org
clinicaltrials.gov
- Clinical trial number NCT01753076 for "Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis" at ClinicalTrials.gov
doi.org
- Jokic N, Gonzalez de Aguilar JL, Dimou L, Lin S, Fergani A, Ruegg MA, et al. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Reports. November 2006, 7 (11): 1162–7. PMC 1679784
. PMID 17039253. doi:10.1038/sj.embor.7400826. - Schmidt ER, Pasterkamp RJ, van den Berg LH. Axon guidance proteins: novel therapeutic targets for ALS?. Progress in Neurobiology. August 2009, 88 (4): 286–301. PMID 19523502. S2CID 207406311. doi:10.1016/j.pneurobio.2009.05.004.
gsk-clinicalstudyregister.com
- GSK: Result Summaries: Compounds > GSK1223249. www.gsk-clinicalstudyregister.com. （原始内容存档于2012-05-27）.
nih.gov
ncbi.nlm.nih.gov
- Jokic N, Gonzalez de Aguilar JL, Dimou L, Lin S, Fergani A, Ruegg MA, et al. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Reports. November 2006, 7 (11): 1162–7. PMC 1679784 . PMID 17039253. doi:10.1038/sj.embor.7400826.
- Schmidt ER, Pasterkamp RJ, van den Berg LH. Axon guidance proteins: novel therapeutic targets for ALS?. Progress in Neurobiology. August 2009, 88 (4): 286–301. PMID 19523502. S2CID 207406311. doi:10.1016/j.pneurobio.2009.05.004.
semanticscholar.org
api.semanticscholar.org
- Schmidt ER, Pasterkamp RJ, van den Berg LH. Axon guidance proteins: novel therapeutic targets for ALS?. Progress in Neurobiology. August 2009, 88 (4): 286–301. PMID 19523502. S2CID 207406311. doi:10.1016/j.pneurobio.2009.05.004.
web.archive.org
- Statement On A Nonproprietary Name Adopted By The USAN Council - Ozanezumab （页面存档备份，存于互联网档案馆）, American Medical Association.
- Phase II - Ozanezumab (GSK1223249). ALS Canada. （原始内容存档于2013-05-10）.
- GSK: Result Summaries: Compounds > GSK1223249. www.gsk-clinicalstudyregister.com. （原始内容存档于2012-05-27）.